Daily pill doubles survival time in deadliest cancer trial
3 reported
A clinical trial has found that a daily pill called daraxonrasib can double survival time in patients with the world’s deadliest cancer, according to a report by The Guardian. Experts described the results as a gamechanger and one of the biggest breakthroughs in decades. The Guardian’s Madeleine Finlay spoke about the drug with Prof Naureen Starling, a consultant medical oncologist at the Royal Marsden hospital, to discuss how daraxonrasib works and its potential impact on patients. The report is based on a single source and has not been cross-referenced with other outlets.
What’s reported
A daily pill named daraxonrasib doubled survival time in patients with the world’s deadliest cancer in a clinical trial.
Experts called the results a gamechanger and one of the biggest breakthroughs in decades.
Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital, discussed the drug with The Guardian’s Madeleine Finlay.
Key figures
Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital
Madeleine Finlay, The Guardian journalist
Sources: The Guardian
